SAN DIEGO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Salona Global Medical Device Corporation (TSXV:SGMD) announced that it will hold an earnings conference call (see details below) to discuss its third quarter 2022 financial results, including details on organic growth for the quarter, deal flow, and acquisition status, on Tuesday, January 17, 2023 at 5:00 pm (Eastern Time) and will issue an earnings press release earlier that morning.
Conference call/Webcast Information:
Fiscal Third Quarter Earnings Call Dial In: +1 (800) 245-3047
Conference ID: SALONA
For more information please contact:
Luke Faulstick
Chief Executive Officer
Tel: 1 (800) 760-6826
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
| Last Trade: | C$0.005 |
| Daily Volume: | 0 |
| Market Cap: | C$299K |
March 17, 2025 November 25, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
